Thursday, 5 November 2026European Markets

XXL Stock Soars Over 34% In Recent Sessions! Discover Why.

Loading stream...

(VIANEWS) - Shares of XXL (XXL.OL) increased 34.86% over five sessions from kr0.7 to kr0.94, making two consecutive gains and further strengthening an upward trend that began last session. As of 14:52 EST Thursday afternoon, its price had reached kr0.94, 54.97% lower than its 52-week high of kr2.09. The Oslo Bors Benchmark Index_GI is up 0.444% from Tuesday and remains on an upward path as well. XXL's last closing price stood at 0.94 which represents two consecutive sessions of gains, expanding on previous gains from its 52-week high of KR2.09

About XXL

XXL ASA is a sports retailer offering a broad selection of equipment and sportswear, fitness equipment, nutrition, outdoor products and hunting products for running, football, golf, water sports racket sports ice hockey. In particular the products provided include running shoes and accessories as well as hunting firearms for fishing wilderness living camping as well as high end bikes bicycle equipment and products which bridge technology with sports/outdoor activities. Established in 2000 with its headquarters located in Oslo Norway.

Yearly Analysis

According to available data, XXL stock is currently trading at kr0.94, significantly below its 52-week high of 2.09 but still higher than its low of 0.57 over the past year. This indicates a considerable decline in value over time. As far as anticipated sales growth is concerned, XXL should experience an estimated 9.9% sales boost this year and then see slower annual increases of 5.3% over time. Regarding XXL's EBITDA (earnings before interest, taxes, depreciation and amortization), their earnings before interest taxes depreciation and amortization currently stands at 118.56, signalling positive earnings and profitable operations despite potential influences such as industry or financial structure that may alter this figure.

Technical Analysis

XXL's stock has been performing exceptionally well, surpassing both its 50-day and 200-day moving averages by an amount equal to 0.93. This indicates an upward trend over both short- and long-term trading cycles. Furthermore, its last reported volume (38504362) exceeded its average volume (5335040), signifying an exceptional trading day for this stock. However, XXL's volatility has been relatively low over the past week; its intraday variation average has ranged between 4.38% to 9.38% for quarter, month, and week periods since October - suggesting relatively stable price movements; investors should remain wary as an increase in volatility could cause greater price swings. According to the stochastic oscillator, XXL stock is currently considered oversold (=20), suggesting it may be undervalued in the market and offering investors an opportunity to purchase into it at lower price points.

Quarter Analysis

According to available data, XXL has experienced exceptional sales growth during its current quarter at 466.1% - an impressive increase over their prior quarter but year-on-year quarterly revenue growth has decreased by 9.5%; its twelve trailing month revenue reached 7.96B. Looking ahead, the company estimates growth of 78.4% for the current quarter and 75% for the following one - numbers which may indicate increased demand for its products or services. Overall, XXL's sales growth and revenue growth figures indicate mixed performance; with strong quarterly growth being experienced but year-on-year revenue growth declining year-on-year. Investors should carefully consider these figures along with any relevant financial information before making investment decisions.

Equity Analysis

Hi! How may I help with your inquiry regarding XXL's Earnings Per Share (EPS) and Return On Equity (ROE) figures?

More news about XXL (XXL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com